Trilaciclib added to topotecan for advanced small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether adding trilaciclib (a medicine given with chemotherapy) can improve outcomes for people with extensive-stage small cell lung cancer who are being treated with topotecan. It compares trilaciclib versus a placebo (inactive pill) while you receive topotecan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extensive-stage small cell lung cancer confirmed by tissue or cell testing
- Your cancer has grown during or after 1st or 2nd chemotherapy, and your first treatment included a platinum drug
- Your doctors can measure or otherwise track your cancer for the study
- You have NOT had trilaciclib or topotecan before for small cell lung cancer
- You have not had other cancer treatments in the last 3 weeks (with limited exceptions)
- You do not have brain metastases that need urgent radiation or steroid treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
This study tests whether adding trilaciclib to a new chemotherapy (sacituzumab tirumotecan) can help people with EGFR-mutant lung cancer that keeps growing after certain targeted treatments. The goal is to see if it slows the cancer and reduces side effects.
This trial tests a combination of four drugs as a first treatment for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and effective. It may be an option for those who have not had prior treatment for advanced disease.
This trial tests a new drug combination (trilaciclib plus docetaxel) for people with advanced lung cancer (NSCLC) whose cancer has progressed after at least one prior treatment. The goal is to see if adding trilaciclib helps the chemotherapy work better with fewer side effects.
This trial tests a new drug called Trilaciclib added to standard cancer immunotherapy and chemotherapy for people with recurrent or metastatic head and neck squamous cell carcinoma that cannot be treated with surgery or radiation. The goal is to see if adding Trilaciclib helps protect the body's blood cells during treatment.
This trial tests an investigational drug called trilaciclib added to standard chemoradiation and immunotherapy for locally advanced esophageal cancer that cannot be surgically removed. The goal is to see if this combination improves treatment outcomes.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.